Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284393 | 0.76 | CRHR1 (0.44) | CRHR1HSD17B10RAPGEF4OPRM1LCK | |
| SCHEMBL15188851 | 0.69 | ALDH1A1 (0.51) | CRHR1RAPGEF4OPRM1SMN1; SMN2LCK | |
| SCHEMBL3286375 | 0.66 | SMN1; SMN2 (0.53) | HSD17B10SMN1; SMN2LCKGAA | |
| SCHEMBL3284966 | 0.65 | CRHR1 (0.71) | CRHR1 | |
| SCHEMBL3286480 | 0.63 | CRHR1 (0.76) | CRHR1 | |
| SCHEMBL3286627 | 0.63 | KMT2A (0.46) | CRHR1RAPGEF4OPRM1SMN1; SMN2LCK | |
| SCHEMBL502929 | 0.62 | RAPGEF4 (1.00) | RAPGEF4 | |
| SCHEMBL14940406 | 0.62 | RAPGEF4 (0.54) | CRHR1RAPGEF4 | |
| SCHEMBL22074675 | 0.62 | HSD17B10 (0.61) | HSD17B10SMN1; SMN2GAA | |
| SCHEMBL8034037 | 0.62 | RAPGEF4 (0.48) | CRHR1RAPGEF4OPRM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714009-B2 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | NPY4R, NR4A3, NR3C2 | CRHR1 4/4885HSD17B10 2322/4885RAPGEF4 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.